The University of Chicago Header Logo

Connection

Russell Z. Szmulewitz to Neoplasm Metastasis

Back to Details
This is a "connection" page, showing publications Russell Z. Szmulewitz has written about Neoplasm Metastasis.
Russell Z. Szmulewitz
Connection Strength
1.311
Neoplasm Metastasis
  1. Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Med. 2014 Nov 26; 12:313.
    View in: PubMed
    Score: 0.355
  2. A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jun 03; 30(11):2384-2392.
    View in: PubMed
    Score: 0.172
  3. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016 Feb 15; 76(3):286-93.
    View in: PubMed
    Score: 0.094
  4. Corticosteroids and prostate cancer: friend or foe? Eur Urol. 2015 May; 67(5):874-5.
    View in: PubMed
    Score: 0.087
  5. Metastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms. Urol Oncol. 2015 Feb; 33(2):70.e1-7.
    View in: PubMed
    Score: 0.087
  6. MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression. Int J Cancer. 2012 Feb 01; 130(3):509-20.
    View in: PubMed
    Score: 0.069
  7. Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). Clin Cancer Res. 2024 Oct 01; 30(19):4318-4328.
    View in: PubMed
    Score: 0.044
  8. Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and =75 Years: ARCHES Post Hoc Analysis. Eur Urol Oncol. 2024 Aug; 7(4):860-869.
    View in: PubMed
    Score: 0.041
  9. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer. 2021 08; 9(8).
    View in: PubMed
    Score: 0.035
  10. Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2021 06; 150:83-94.
    View in: PubMed
    Score: 0.035
  11. Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2021 07 15; 27(14):4077-4088.
    View in: PubMed
    Score: 0.034
  12. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol. 2021 04 20; 39(12):1371-1382.
    View in: PubMed
    Score: 0.034
  13. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. J Urol. 2021 May; 205(5):1361-1371.
    View in: PubMed
    Score: 0.034
  14. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. Eur Urol. 2020 10; 78(4):603-614.
    View in: PubMed
    Score: 0.032
  15. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019 11 10; 37(32):2974-2986.
    View in: PubMed
    Score: 0.031
  16. MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res. 2018 08 01; 24(15):3668-3680.
    View in: PubMed
    Score: 0.028
  17. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212.
    View in: PubMed
    Score: 0.025
  18. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76.
    View in: PubMed
    Score: 0.022
  19. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One. 2013; 8(1):e53701.
    View in: PubMed
    Score: 0.019
  20. Metastasis-suppressor genes in clinical practice: lost in translation? Nat Rev Clin Oncol. 2011 Jun; 8(6):333-42.
    View in: PubMed
    Score: 0.017
  21. New paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells. Cancer Lett. 2008 Dec 08; 272(1):12-22.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.